Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2024
Avapritinib for treating advanced systemic mastocytosis (TA1012)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 November 2024
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 October 2024
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)Product type:GuidanceProgramme:Highly specialised technologies guidanceLast updated: 20 September 2024Published: 10 October 2018
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 September 2024
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)Product type:GuidanceProgramme:NICE guidelinePublished: 6 March 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 December 2023
Jaundice in newborn babies under 28 days (CG98)Product type:GuidanceProgramme:Clinical guidelineLast updated: 31 October 2023Published: 19 May 2010
Ruxolitinib for treating polycythaemia vera (TA921)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 February 2023
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2022
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) (TA845)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 November 2022
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Midostaurin for treating advanced systemic mastocytosis (TA728)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 May 2021
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Volanesorsen for treating familial chylomicronaemia syndrome (HST13)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 21 October 2020
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (DG20)Product type:GuidanceProgramme:Diagnostics guidanceLast updated: 19 February 2020Published: 10 February 2016
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2019
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)Product type:GuidanceProgramme:NICE guidelinePublished: 23 May 2019
Eltrombopag for treating chronic immune thrombocytopenia (TA293)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 24 July 2013
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 27 April 2011
Tocilizumab for treating giant cell arteritis (TA518)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 April 2018
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2016
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (MTG28)Product type:GuidanceProgramme:Medical technologies guidancePublished: 2 March 2016
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 28 January 2015
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Neutropenic sepsis: prevention and management in people with cancer (CG151)Product type:GuidanceProgramme:Clinical guidelinePublished: 19 September 2012
Sickle cell disease: managing acute painful episodes in hospital (CG143)Product type:GuidanceProgramme:Clinical guidelinePublished: 27 June 2012
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2011
Helge for detecting haemolysis (MIB225)Product type:AdviceProgramme:Medtech innovation briefingPublished: 1 September 2020
CytoSorb therapy for sepsis (MIB87)Product type:AdviceProgramme:Medtech innovation briefingPublished: 29 November 2016
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)Product type:AdviceProgramme:Medtech innovation briefingPublished: 30 September 2015
Autoimmune haemolytic anaemia: rituximab (ESUOM39)Product type:AdviceProgramme:Evidence summaryPublished: 10 February 2015
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)Product type:AdviceProgramme:Evidence summaryPublished: 21 October 2014
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)Product type:AdviceProgramme:Evidence summaryPublished: 29 January 2013